Skip to main content

Table 1 Study characteristics

From: Budget impact analysis of breast cancer medications: a systematic review

Study

Year

Country

Funding

Perspective

Study type

Study base

Intervention

Comparator

Population

Population size

Ivanov et al. [40]

2021

Russia

N.R

Federal Compulsory Health Insurance Fund

CMA + BIA

Model

PO vinorelbine

Ixabepilone

Metastatic BC

1000 hypothetical patients

Elsamany et al. [37]

2020

Saudi Arabia

Roche Products Saudi Arabia

Governmental health sector

BIA only

Model

SC trastuzumab

IV trastuzumab

HER 2 + BC

394 newly diagnosed cases/ year

Pouwels et al. [27]

2020

Netherlands

Netherlands Organization for Health Research and Development, Eisai, Novartis BV, Roche, Pfizer and Eli Lilly

Dutch societal

CEA + BIA

Real-world

Eribulin

Non-eribulin chemotherapy

The Southeast Netherlands advanced BC registered patients

–

Genuino et al. [38]

2019

Philippines

Mahidol University and the International

Decision Support Initiative (iDSI)

Healthcare system and societal

CUA + BIA

Model

Adjuvant

trastuzumab

Standard chemotherapy alone

HER 2 + 

early-stage BC

64,046

Prevalent

Cases in 5 years, 21,057

New cases (23.17% HER 2 + , 80% early stage)

Avxentyev et al. [41]

2019

Russia

Pfizer

Russian healthcare system

CMA + BIA

Model

CDK 4/6 inhibitor + letrozole

Another CDK 4/6 inhibitor + letrozole

HR + HER 2 -advanced BC

8098–8221 newly diagnosed patients/ year

Lee et al. [28]

2019

28 European Countries

Chung-Ang University research

Payer

BIA only

Model

Biosimilar Trastuzumab (CT-P6)

Originator trastuzumab

HER 2 + BC

Early BC: 79,723 (2018) Metastatic BC: 14,844 (2018)

Mistry et al. [34]

2019

USA

Novartis

US payer

BIA only

Model

Ribociclib + letrozole

Letrozole alone, palbociclib + letrozole, fulvestrant + anastrozole, fulvestrant alone, exemestane, tamoxifen, anastrozole alone, palbociclib + Fulvestrant, Fulvestrant + letrozole, and eribulin

Post-menopausal women with HR + /HER2 -advanced /metastatic BC

263 cases in a cohort of 1 million members at first year and increase in subsequent years

Clarke et al. [33]

2017

UK

No fund

English NHS payer

CEA + BIA

Model

Different durations of adjuvant

–

Early BC

–

trastuzumab

Cesarec et al. [26]

2017

Croatia

No fund

Public healthcare

BIA only

Model

Biosimilar Trastuzumab

–

BC

479 cases in 1 year

Lewis et al. [39]

2015

Kazakhstan

Novartis Pharma AG

N.R

BIA only

Model

Everolimus + letrozole/anastrozole

Letrozole/anastrozole,

Post-menopausal HR + HER2 -advanced BC

776 prevalent, and 133, 145, 157, and 170 newly diagnosed in 2015–2018

Chemotherapy,

Tamoxifen

Benjamin et al. [30]

2013

France

GSK

French National Health Insurance

BIA only

Model

Trastuzumab-based therapy

Lapatinib + capecitabine

HER2-positive metastatic BC

4182 cases (73% trastuzumab-based therapy, 27% lapatinib + capecitabine)

Xie et al. [43]

2013

US

Novartis

US payer

BIA only

Model

Exemestane + everolimus

Exemestane

Fulvestrant Tamoxifen

HER2-positive advanced BC

72 cases / 1 million receiving their first treatment after letrozole or anastrozole failure, and 159 cases / 1 million receiving a second treatment after failing letrozole or anastrozole and the first treatment

Purmonen et al. [31]

2010

Finland

Finnish Office for Health Technology Assessment (Finohta)

Single hospital district

BIA only

Model

Trastuzumab

–

Early BC

86.6/100,000 in 2006

Ho et al. [36]

2009

US

Bristol-Myers Squibb Company (BMS)

Payer

BIA only

Model

Ixabepilone

Various anti-cancer medications

Treatment-resistant metastatic BC

570 cases/1 million

Neyt et al. [32]

2008

Belgium

N.R

Payer

CEA + BIA

Model

Trastuzumab

ST

Early BC

–

Millar et al. [42]

2007

Australia

N.R

Australian health system

CEA + BIA

Model

Trastuzumab

ST

Early BC

–

Marchetti et al. [29]

2004

Italy

AstraZeneca SpA

Italian National Health Service

CUA + BIA

Model

Third-Generation Aromatase

Tamoxifen, megestrol, paclitaxel, docetaxel, vinorelbine

Advanced BC

–

Inhibitors